Vir Biotechnology (VIR) director restructures 16,000-share holding with Alta Partners fund
Rhea-AI Filing Summary
Vir Biotechnology, Inc. director Robert J. More reported entity-level share transfers involving 16,000 shares of common stock. On 2026-08-11, 8,000 shares held directly for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred for no consideration, and 8,000 shares were correspondingly recorded as held indirectly by APNG 1 in connection with the vesting of restricted stock unit awards. Following these transactions, More reports 40,656 shares held directly and 517,917 shares held indirectly through APNG 1, with beneficial ownership of the indirect holdings disclaimed except for his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
MORE ROBERT J
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Common Stock F1 | 8,000 | $0.00 | $0.00 |
| Other | Common Stock F1, F2 | 8,000 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 40,656 shares (Direct);
Common Stock — 517,917 shares (Indirect, See footnote)
Footnotes (2)
- F1. Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards.
- F2. The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
Key Figures
Shares transferred (dispose leg): 8,000 shares
Shares transferred (acquire leg): 8,000 shares
Price per share: $0.00 per share
+3 more
6 metrics
Shares transferred (dispose leg)
8,000 shares
Common Stock transferred out of direct holdings on 2026-08-11
Shares transferred (acquire leg)
8,000 shares
Common Stock recorded as indirectly held through APNG 1 on 2026-08-11
Price per share
$0.00 per share
Both J-code transactions in connection with RSU vesting
Direct holdings after transaction
40,656 shares
Common Stock held directly by Robert J. More following 2026-08-11
Indirect holdings after transaction
517,917 shares
Common Stock held indirectly through Alta Partners NextGen Fund I, L.P.
Restructuring shares total
16,000 shares
Total shares involved in J-code restructuring transactions
Key Terms
restricted stock unit (RSU) awards, beneficial ownership, pecuniary interest, Section 16 of the Securities Exchange Act of 1934
4 terms
restricted stock unit (RSU) awards financial
"in connection with the vesting of restricted stock unit (RSU) awards"
beneficial ownership financial
"may be deemed to beneficially own the shares held by APNG 1"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest"
Section 16 of the Securities Exchange Act of 1934 regulatory
"beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934"
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
FAQ
What did Vir Biotechnology (VIR) director Robert J. More report in this Form 4?
Robert J. More reported two non-derivative transactions on 2026-08-11 involving a total of 16,000 common shares. These were internal transfers related to restricted stock unit (RSU) vesting between his direct holdings and shares held for Alta Partners NextGen Fund I, L.P.
What are Robert J. More’s Vir Biotechnology (VIR) holdings after these transactions?
After the 2026-08-11 transfers, Robert J. More reports 40,656 shares of Vir Biotechnology common stock held directly and 517,917 shares held indirectly through Alta Partners NextGen Fund I, L.P., with beneficial ownership of the indirect shares disclaimed except for his pecuniary interest.
How is Alta Partners NextGen Fund I, L.P. involved in these Vir Biotechnology (VIR) transactions?
The filing states shares held for Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred for no consideration to APNG 1 upon RSU vesting. Robert J. More is a managing director of APNG 1’s general partner and may be deemed to beneficially own those shares, subject to a disclaimer.
Does Robert J. More fully acknowledge beneficial ownership of APNG 1’s Vir Biotechnology (VIR) shares?
No. He may be deemed to beneficially own APNG 1’s shares but disclaims beneficial ownership of those securities, except to the extent of his pecuniary interest, and notes the report should not be considered an admission of beneficial ownership under Section 16.
AI-generated analysis. How Rhea-AI works. Not financial advice.
